IL142980A0 - Nucleic acid constructs for genetic immunization - Google Patents

Nucleic acid constructs for genetic immunization

Info

Publication number
IL142980A0
IL142980A0 IL14298099A IL14298099A IL142980A0 IL 142980 A0 IL142980 A0 IL 142980A0 IL 14298099 A IL14298099 A IL 14298099A IL 14298099 A IL14298099 A IL 14298099A IL 142980 A0 IL142980 A0 IL 142980A0
Authority
IL
Israel
Prior art keywords
nucleic acid
acid constructs
molecules
genetic immunization
sequence encoding
Prior art date
Application number
IL14298099A
Other languages
English (en)
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of IL142980A0 publication Critical patent/IL142980A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14298099A 1998-11-05 1999-11-05 Nucleic acid constructs for genetic immunization IL142980A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10716998P 1998-11-05 1998-11-05
PCT/US1999/026291 WO2000026385A1 (fr) 1998-11-05 1999-11-05 Produits de recombinaison d'acide nucleique pour immunisation genetique

Publications (1)

Publication Number Publication Date
IL142980A0 true IL142980A0 (en) 2002-04-21

Family

ID=22315199

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14298099A IL142980A0 (en) 1998-11-05 1999-11-05 Nucleic acid constructs for genetic immunization

Country Status (13)

Country Link
EP (1) EP1119630B1 (fr)
JP (1) JP2002528123A (fr)
AT (1) ATE315658T1 (fr)
AU (1) AU775939B2 (fr)
CA (1) CA2349505A1 (fr)
CY (1) CY1105600T1 (fr)
DE (1) DE69929470T2 (fr)
DK (1) DK1119630T3 (fr)
ES (1) ES2257879T3 (fr)
IL (1) IL142980A0 (fr)
NZ (1) NZ512078A (fr)
PT (1) PT1119630E (fr)
WO (1) WO2000026385A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
EP1220697B1 (fr) 1999-10-11 2004-12-29 Felton International, Inc. Protecteur universel contre les infections pour injecteurs sans aiguille
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
PT1294893E (pt) * 2000-06-22 2006-08-31 Ucb Pharma Ltd Modificacao do antigenio nuclear de hepatite b
JP2004509621A (ja) * 2000-09-19 2004-04-02 トリペップ　アクチ　ボラゲット 病原体上の受容体に対して抗体を再指向させるリガンド／受容体特異性変換体
WO2002094313A2 (fr) * 2001-05-18 2002-11-28 Powderject Vaccines, Inc. Composition de vaccin
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
WO2004028560A1 (fr) * 2002-09-27 2004-04-08 Powderject Research Limited Particules recouvertes d'acide nucleique
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
US7318926B2 (en) 2003-02-06 2008-01-15 Tripep Ab Glycosylated specificity exchangers
JP2010505883A (ja) 2006-10-12 2010-02-25 ザ ユニバーシティー オブ クイーンズランド 免疫応答を調節するための組成物および方法
ES2622562T3 (es) 2008-12-09 2017-07-06 Pfizer Vaccines Llc Vacuna de péptido CH3 de IgE
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
WO2011027257A2 (fr) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Vaccin pcsk9
WO2011154878A1 (fr) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Vaccin peptidique ige ch3
WO2012058715A1 (fr) 2010-11-01 2012-05-10 University Of Technology, Sydney Agents immuno-modulateurs et leurs utilisations
MX343830B (es) 2011-02-11 2016-11-24 Univ Pennsylvania Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
WO2012131504A1 (fr) 2011-03-02 2012-10-04 Pfizer Inc. Vaccin à base de pcsk9

Also Published As

Publication number Publication date
EP1119630A1 (fr) 2001-08-01
EP1119630B1 (fr) 2006-01-11
CY1105600T1 (el) 2010-07-28
DE69929470D1 (de) 2006-04-06
NZ512078A (en) 2004-01-30
AU775939B2 (en) 2004-08-19
WO2000026385A9 (fr) 2000-10-26
ES2257879T3 (es) 2006-08-01
AU2022200A (en) 2000-05-22
JP2002528123A (ja) 2002-09-03
CA2349505A1 (fr) 2000-05-11
ATE315658T1 (de) 2006-02-15
PT1119630E (pt) 2006-05-31
DK1119630T3 (da) 2006-05-15
DE69929470T2 (de) 2006-08-24
WO2000026385A1 (fr) 2000-05-11

Similar Documents

Publication Publication Date Title
IL142980A0 (en) Nucleic acid constructs for genetic immunization
EP0460076A4 (en) Genetically engineered immunoglobulins
ATE518956T1 (de) Expressionsvektoren zur stimulierung einer immunantwort und verfahren zu deren verwendung
IL188875A0 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
WO2001073059A3 (fr) 38692 et 21117, nouvelles molecules de phosphatase a double specificite et leurs utilisations
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
WO2000075358A3 (fr) Molecules toll et leurs utilisations
FI20070041A (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin
WO2000063385A3 (fr) Immunisation de l'acide nucleique
WO2002103015A3 (fr) Nouvelle molecule de transport abca10 et utilisations de celle-ci
ATE276277T1 (de) Monoklonale antikörper gegen antigene, die durch hämatopoietische helferzellen exprimiert werden
MXPA03010527A (es) Composicion de vacuna.
WO2001094390A3 (fr) 52906, 33408, et 12189, nouveaux elements de la famille de canaux de potassium et leurs utilisations
WO2000047227A3 (fr) IMMUNISATION CONTRE $i(MYCOBACTERIUM TUBERCULOSIS)
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
WO2002070691A3 (fr) Nouveau transporteur abcg4 et ses utilisations
WO2002024743A3 (fr) 55063, nouveau membre de la famille nmda humaine et ses applications
WO2002059314A3 (fr) 52020, nouvel antigene associe a un melanome humain et ses utilisations
WO2002095032A3 (fr) 69087, 12821, et 15418, procedes et compositions de proteines humaines et leurs utilisations
WO2002002761A3 (fr) 57658, nouvelle uridine kinase humaine et utilisations correspondantes
MXPA01011563A (es) Una novedosa proteina 5 relacionada al factro-h y anticuerpos relacionados.
WO2001064902A3 (fr) Membres de la famille des transferases 46867 et leurs utilisations
WO2001090320A3 (fr) 58224, un nouveau membre de la famille de l'helicase et utilisations de ce dernier
WO2001083721A3 (fr) La 32132, nouveau membre de la famille des fucosyltransferases et ses utilisations